Conversations on Colorectal Cancer
Between 50 and 60 percent of patients diagnosed with colorectal cancer will develop metastases during the course of their disease, spreading to the lungs, liver, or other secondary location.
To help physicians tackle this very real threat facing their patients, Conversations on Colorectal Cancer focuses on the current guidelines and therapeutic landscape for metastatic colorectal cancer (mCRC).
This non-certified educational series is sponsored by Lilly. Content for this series is produced and controlled by ReachMD. This series is intended for healthcare professionals only.
Sponsored by
Episodes 1-6 of 6
- 2
Conversations on Colorectal Cancer
Characteristic Clinical Presentations of Tumor Sidedness: Diagnostic & Pr...
- 0
Conversations on Colorectal Cancer
Comparing Anti-EGFR in Left vs. Right-Sided Colorectal Cancer Tumors: Surviva...
- 0
Conversations on Colorectal Cancer
An Oncologist’s Keys to Managing Adverse Events in mCRC Care
Global Oncology Academy
Tumor Sidedness in mCRC: Translating the Latest Research Findings into Practice
Global Oncology Academy
mCRC ‘State of the Union’: Current & Emerging Research Avenues to Know
Conversations on Colorectal Cancer
Addressing Gaps in Biomarker Testing for mCRC at Diagnosis
